ARTICLE | Company News
Schwarz Pharma, AmorePacific Corp. deal
February 23, 2004 8:00 AM UTC
Schwarz received exclusive global rights to develop, market and manufacture AmorePacific's PAC20030 vanilloid receptor 1 ( VR1) antagonist and back-up compounds to treat pain and urinary incontinence....